CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
简要研究报告：深度免疫表型分析揭示 CD19 CAR-T 细胞随时间的稳定性
英文原题：Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time.
查看英文原题
Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
变异性或稳定性可能对CD19 CAR-T 细胞的治疗成功和毒性产生影响。我们开展了一项前瞻性观察性研究，纳入12例接受Tisagenlecleucel治疗CD19+ B细胞恶性肿瘤的患者。使用31色光谱流式细胞术panel，我们分析了CAR-T 细胞输注前以及6个月随访期间纵向的CAR-T 细胞亚群分化阶段和耗竭标志物。CAR-T 细胞上的大多数活化标志物随时间显示出稳定的表达模式，且与治疗反应或毒性无关。无监督聚类分析揭示了与免疫细胞相关神经毒性综合征发生相关的CAR-T 细胞产品的免疫特征。值得在独立患者队列中验证，CAR-T 细胞产品的深入表型分析以及细胞输注后的纵向监测可能成为提高CAR-T 细胞治疗疗效和安全性的有价值工具。
展开英文摘要原文
Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells.
We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19 + B-cell malignancies. Using a 31-color spectral flow cytometry panel, we analyzed differentiation stages and exhaustion markers of CAR T-cell subsets prior to CAR T-cell infusion and longitudinally during 6 months of follow-up. The majority of activation markers on CAR T-cells showed stable expression patterns over time and were not associated with response to therapy or toxicity.
Unsupervised cluster analysis revealed an immune signature of CAR T-cell products associated with the development of immune cell-associated neurotoxicity syndrome. Warranting validation in an independent patient cohort, in-depth phenotyping of CAR T-cell products as well as longitudinal monitoring post cell transfer might become a valuable tool to increase efficacy and safety of CAR T-cell therapy.
论文信息
- 作者
- Odak I、Bayir LM、Riemann L、Sikora R、Schneider J、Xiao Y、Möhn N、Skripuletz T
- 单位
- Institute of Immunology, Hannover Medical School, Hannover, Germany.Germany
- 文献类型
- 观察性研究 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 38318174 · DOI 10.3389/fimmu.2024.1298598
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →